Exendin-4 Is A Treatment For Type 2 Diabetes

Exendin-4是GLP-1受体的激动剂，正在开发用于治疗2型糖尿病。它是促胰岛素的，其生物学作用比GLP-1本身更持久。在我们对非糖尿病和糖尿病受试者的第一项研究中，我们发现它也比GLP-1更有效。我们现在每天皮下注射exendin-4给2型糖尿病受试者一个月，分两次给药。我们发现，在一个月的过程中，它降低了糖化血红蛋白0.8%，同时在研究期间保持促胰岛素活性。目前，这种化合物正被FDA作为2型糖尿病的候选药物快速跟踪。目标是获得可用于治疗2型糖尿病的exendin-4的经皮制剂，以消除皮下注射的必要性。我们参与了这些正在进行的研究。

Exendin-4, an agonist of the GLP-1 receptor, is being developed as a treatment for type 2 diabetes. It is insulinotropic, and its biological actions are more long-lived than that of GLP-1 itself. In our first study of non-diabetic and diabetic subjects we showed that it was also more potent than GLP-1. We have now given exendin-4 daily subcutaneously to type 2 diabetic subjects for one month, in two divided doses. We showed that during the course of the month it lowered glycated hemoglobin by 0.8%, while maintaining insulinotropic activity for the duration of the study. Presently this compound is being fast-tracked by FDA as a candidate agent for type 2 diabetes. The goal is to have a transdermal preparation of exendin-4 available for treating type 2 diabetes so as to eliminate the necessity of subcutaneous injections. We are involved in these ongoing studies.